DOCSLIB.ORG

Genetic Epidemiology of Essential Hypertension

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetic Epidemiology of Essential Hypertension Journal of Human Hypertension (1999) 13, 225–229 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Genetic epidemiology of essential hypertension I Gavras1, A Manolis1,2 and H Gavras1 1Hypertension and Atherosclerosis Section of the Department of Medicine, Boston University School of Medicine, Boston, MA, USA; 2Tzanio Hospital, Piraeus, Greece This review article is intended to introduce the unini- heritable anthropometric, clinical or biochemical tiated clinician to the basic concepts, aims and early characteristics; and some applications of genetic epi- findings of the genetic epidemiology of hypertension. It demiologic techniques, such as linkage and association separates the rare monogenic ‘Mendelian’ hypertensive studies of certain gene polymorphisms with hyperten- disorders from the vast majority of patients with essen- sion using affected sibling pairs and large sibships or tial hypertension, which is a complex, polygenic, multi- wide genomic screens comparing affected and unaffec- factorial disorder resulting from interaction of several ted populations. Although so far there is no genotypic genes with each other and with the environment. It high- variation proven to be causally related to essential lights some clinical strategies used to enhance hypertension, its intermediate phenotypes or any of its searches for ‘candidates genes’, such as subgrouping complications, it is hoped that new, more efficient of populations into relatively homogenous groups or methods of genetic analysis will yield clinically mean- ‘intermediate phenotypes’ according to presumably ingful information. Keywords: gene polymorphisms; candidate genes; monogenic disorders; intermediate phenotypes; polygenic multifactorial traits Hypertensive phenotypes the interaction of several genes with each other and with the environment result in different phenotypes. Essential hypertension results from the interaction Hypertension is often associated with insulin of hereditary and environmental factors and is one resistance ranging from borderline fasting of the leading causes of premature cardiovascular hyperglycaemia/hyperinsulinaemia to clinically morbidity and mortality. Blood pressure levels are overt diabetes mellitus type II. The frequent coexist- highly correlated among family members, a fact ence of the two conditions has suggested a common attributable to either common genetic background or aetiologic background.4 If left untreated, hyperten- shared environment and lifestyle habits, or both. sion results in target organ complications, such as Studies of familial aggregation and rates of concord- congestive heart failure, stroke and renal failure, all ance among monozygotic and dizygotic twins sug- of which can be prevented to various extents by gest that genes may contribute as much as 40% of 1 optimal blood pressure control. Coronary artery dis- the risk to this disorder. High blood pressure, ease is also a frequent complication of both hyper- defined as systolic pressure у140 mm Hg and dia- у tension and diabetes, but appears to be less prevent- stolic 90 mm Hg, is characterised by a high but able by optimal blood pressure control.5 For these variable prevalence rate of 15–25% among popu- reasons, it is now accepted that arterial blood press- lations.2 But blood pressure does not have a bimodal ure elevation per se is only one of the factors con- distribution into normal and abnormal groups. tributing to target organ damage and does not con- Rather, it is a quantitative trait with wide pheno- sistently predict the occurrence or severity of typic variation and a continuous distribution, where hypertensive complications. In other words, hyper- an arbitrary cutoff line at some point of the Gaussian curve separates normal from abnormal. This indi- tension is too broad a phenotype. Over the years several efforts have been made to cates that hypertension is a complex trait, ie, a 5 phenotype that does not follow the classic Mendel- classify essential hypertensive into subtypes or ian rules of dominant or recessive inheritance ‘intermediate phenotypes,’ ie, subgroups homo- attributable to a single gene locus.3 More likely, it is geneous for one or more traits that might have diag- a polygenic and multifactorial disorder, in which nostic or prognostic significance. Various clinical or biochemical characteristics have been chosen in an effort to better define patients at risk of compli- cations. An early such effort was the classification Correspondence: Dr Haralambos Gavras, Chief, Hypertension & into renin subgroups (ie, patients with high, normal Atherosclerosis Section, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, USA or low plasma renin activity in relation to their Received 15 October 1998; revised 16 November 1998; accepted blood pressure and state of sodium balance). It was 10 December 1998 shown in both retrospective and prospective surveys Genetic epidemiology of essential hypertension I Gavras et al 226 that high-renin patients are at increased risk of myo- partly responsible for these findings, it is felt that cardial infarction,6,7 a finding in agreement with the genetically determined characteristics play an equal demonstration that excess angiotensin II of exogen- or more important role.11–14 Differences in the bio- ous or endogenous origin can produce myocardial chemical and endocrine profiles of black hyperten- infarcts.8,9 sives suggest different pathophysiologic mech- A trait deemed to be useful for classification into anisms than in white hypertensives.15 A prime subgroups that would enhance subsequent genetic example of such a biological difference is the analysis, should be pathogenically meaningful and increased frequency and magnitude of salt sensi- show evidence of heritability. Because essential tivity (ie, magnitude of blood pressure rise in hypertension is a complex disorder, in which many response to a sodium load), which is encountered different genes at various loci are likely to be in about three-quarters of hypertensive black involved, it is expected that phenotypically different patients.16 Salt sensitivity is associated with dimin- subjects may present with different constellations of ished ability to excrete a sodium load, and hence gene mutations. Thus, searching for underlying gen- tendency to retain salt, which is attributable to a var- etic causes might be more likely to be fruitful in sub- iety of mechanisms, including alterations in cation populations classified according to intermediate transport across cell membranes, abnormal renal phenotypes. Presumably heritable clinical charac- haemodynamics, and decreased generation of intra- teristics, that have been used to subdivide the hyper- renal natriuretic substances such as kinins, atrial tensive population, include obesity (defined by the natriuretic peptides, prostaglandins and dopamine. body mass index), abdominal adiposity (defined by Black hypertensives also tend to exhibit differences the waist-to-hip ratio), early onset of hypertension in other endocrine characteristics, such as low (eg, before age 50 years), excessive severity of hyper- plasma renin activity, higher levels of endothelin,17 tension (eg, requiring triple drug regimen), hyperres- augmented alpha-adrenergic receptor reactivity, ponsiveness to adrenergic stimuli, salt sensitivity, higher levels of plasma vasopressin (AVP) and etc. Biochemical traits include elevated fasting glu- accentuated hypotensive response to an antivaso- cose and insulin levels, elevated circulating levels pressor AVP antagonist.18 It has also been proposed, of pressor hormones such as renin, catecholamines but not uniformly accepted, that black subjects have and vasopressin, altered characteristics of alpha- relative insulin resistance.15 Of particular interest is adrenergic receptors, decreased activity of the kal- the fact that some of these racial differences have likrein-kinin system, different hormonal responses been observed not only in black hypertensives but to salt loading, etc. Several of these traits have been also in black normotensives compared to age and shown (or are predicted) to coexist in the same indi- gender-matched Caucasians. For example, in a nor- vidual. For example, low-renin individuals are motensive population, lower levels of urinary kal- likely to have low kallikrein excretion and high cir- likrein were reported not only in black vs Caucasian culating vasopressin. Other biochemical parameters, adults19 but also in children.20 In fact, it is possible such as angiotensin-converting enzyme and angio- that low levels of kallikrein might be one reason for tensinogen levels, lipid profile, etc, have also been lack of a local renoprotective effect of kinins and reported to differ among hypertensive populations increased propensity of black hypertensives to renal and possibly contribute to cardiovascular risk. damage, even under good blood pressure control. A common intermediate phenotype is the so- There is strong clinical evidence suggesting that, called metabolic syndrome X. This consists of a con- although salt-sensitivity tends to increase with age, stellation of clinical and biochemical character- it has a large heritable component.21 The high preva- istics, including hypertension, abdominal adiposity lence of salt-sensitivity described in African Amer- (‘apple shape’), hyperlipidaemia, hyperglycaemia icans appears to be also present in native Africans, and hyperinsulinaemia.4 Each one of these charac- as
Load more

Recommended publications
  • Estimation of DNA Contamination and Its Sources in Genotyped Samples
    Gregory Zajac ORCID iD: 0000-0001-6411-9666 Estimation of DNA contamination and its sources in genotyped samples Gregory J. M. Zajac1; Lars G. Fritsche1; Joshua S. Weinstock1; Susan L. Dagenais2; Robert H. Lyons2; Chad M. Brummett3; Gonçalo. R. Abecasis1 1) Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI; MI; 2) Department of Biological Chemistry and DNA Sequencing Core, University of Michigan, Ann Arbor, MI; 3) Department of Anesthesiology, Division of Pain Medicine, University of Michigan Medical School, Ann Arbor, MI. Corresponding author: Gregory JM Zajac 734-763-5315 [email protected] University of Michigan School of Public Health - Department of Biostatistics 1415 Washington Heights Ann Arbor, MI 48109-2029 Grant Numbers: HG007022 Author Manuscript This is the author manuscript accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/gepi.22257. This article is protected by copyright. All rights reserved. Abstract Array genotyping is a cost-effective and widely used tool that enables assessment of up to millions of genetic markers in hundreds of thousands of individuals. Genotyping array data are typically highly accurate but sensitive to mixing of DNA samples from multiple individuals prior to or during genotyping. Contaminated samples can lead to genotyping errors and consequently cause false positive signals or reduce power of association analyses. Here, we propose a new method to identify contaminated samples and the sources of contamination within a genotyping batch.
    [Show full text]
  • Fifty Years of Genetic Epidemiology, with Special Reference to Japan
    J Hum Genet (2006) 51:269–277 DOI 10.1007/s10038-006-0366-9 MINIREVIEW Newton E. Morton Fifty years of genetic epidemiology, with special reference to Japan Received: 13 December 2005 / Accepted: 18 December 2005 / Published online: 15 February 2006 Ó The Japan Society of Human Genetics and Springer-Verlag 2006 Abstract Genetic epidemiology deals with etiology, dis- Introduction tribution, and control of disease in groups of relatives and with inherited causes of disease in populations. It The Japan Society of Human Genetics (JSHG) was took its first steps before its recognition as a discipline, established at a time when the science it represented was and did not reach its present scope until the Human growing so explosively that Carlson (2004) signalised the Genome Project succeeded. The intimate relationship death of classical genetics. Compared to their predeces- between genetics and epidemiology was discussed by sors, geneticists in 1956 were more distrustful of eugenics Neel and Schull (1954), just a year after Watson and and more committed to cytogenetics, biochemistry, and Crick reported the DNA double helix, and 2 years be- medical genetics, but not yet prepared for the genomic fore human cytogenetics and the Japan Society of Hu- revolution that the double helix would ultimately bring man Genetics were founded. It is convenient to divide (Yanase 1997). Population genetics was beginning to the next half-century into three phases. The first of these split into two major branches, one concerned with events (1956–1979) was before DNA polymorphisms were that took place in the past under poorly known forces of typed, and so the focus was on segregation and linkage systematic pressure and chance (evolutionary genetics), of major genes, cytogenetics, population studies, and the other dealing with etiology, distribution, and control biochemical genetics.
    [Show full text]
  • Manual for Conducting a Large-Scale GWAS and Whole Genome
    (COVNET) NIH Lead Investigator: Stephen Chanock, M.D. ([email protected]) Director, Division of Cancer Epidemiology and Genetics, NCI NIH Investigators: Sharon Savage, M.D. ([email protected]) Lisa Mirabello, Ph.D. ([email protected]) Meredith Yeager, Ph.D. ([email protected]) Mitchell Machiela, Sc.D. ([email protected]) Joshua Sampson, Ph.D. ([email protected]) Amy Hutchinson, M.S. ([email protected]) Belynda Hicks, M.S. ([email protected]) Division of Cancer Epidemiology and Genetics, NCI Mary Carrington, Ph.D. ([email protected]) Center for Cancer Research, NCI Leslie Biesecker, M.D. ([email protected]) Teri Manolio, M.D., Ph.D. ([email protected]) National Human Genome Research Institute Steven Holland, M.D. ([email protected]) National Institute of Allergy and Infectious Diseases Project Manager Vibha Vij, M.S., MPH ([email protected]) Division of Cancer Epidemiology and Genetics, NCI Website: https://dceg.cancer.gov/research/how-we-study/genomic-studies/covnet Table of Contents Sections 1.0 Background and Rationale for a Large Crowdsourced GWAS of COVID19 Infection ...... 2 2.0 Biospecimens: genomic DNA, blood/blood products, buccal cells/saliva .......................... 6 3.0 Patient Phenotypes ............................................................................................................. 10 4.0 Genotyping and Imputation ............................................................................................... 10 5.0 Analysis Plan ....................................................................................................................
    [Show full text]
  • M21-515 Fundamentals of Genetic Epidemiology Summer 2018
    M21-515 Fundamentals of Genetic Epidemiology Summer 2018 Revised: 7/13/2018 Course Masters Treva Rice, Ph.D. ([email protected]) Yun Ju Sung, Ph.D. ([email protected]) Lab Instructor Oyomoare Osazuwa-Peters ([email protected]) Grading Computer Lab Assignments 30% Daily Quiz 30% Midterm Exam (covers lectures / homework 1-5) 20% Final Project 20% Final Grade (+/– letter grades) Software Software packages include: 1. R (http://www.r-project.org/) 2. PEDSTATS, Merlin, QTDT (http://www.sph.umich.edu/csg/abecasis) 3. PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/) Textbook Austin, MA. Genetic Epidemiology: Methods & Applications 2013, CABI: Oxfordshire, UK. Format 2-week INTENSIVE course Morning lecture: 9:00 am – 12:00 noon Afternoon computer lab: 1:30 pm – 4:00 pm 10-minute break ~ every hour 1st Homework Due first day of class, Textbook (Chapters 1-2) Assignment On-line genetics tutorial, Chapters 3, 4, and 6 (http://anthro.palomar.edu/tutorials/biological.htm) Prerequisite 1) Knowledge of R programming, either having taken the MSIBS summer R-course or experience in R-programming; 2) experience in Linux/Unix operating system. The core competency for the Fundamentals of Genetic Epidemiology course (M21-515) is for students to understand basic concepts, methods and analytical approaches in genetic epidemiology. Learning objectives are to • Understand familial resemblance, heritability and family study designs • Appreciate maximum likelihood methods and hypothesis testing • Be aware of selected molecular and population genetics principles, including Hardy-Weinberg Equilibrium • Grasp the basic concepts and principles underlying genetic linkage and association • Be able to perform analysis in heritability, linkage and association using selected software and critically evaluate and interpret the corresponding results Page 1 of 10 Additional Information 1.
    [Show full text]
  • Genetic Epidemiology of Health Disparities in Allergy and Clinical Immunology
    Molecular mechanisms in allergy and clinical immunology (Supported by an unrestricted educational grant from Genentech, Inc. and Novartis Pharmaceuticals Corporation) Series editors: William T. Shearer, MD, PhD, Lanny J. Rosenwasser, MD, and Bruce S. Bochner, MD Reviews and feature articles Genetic epidemiology of health disparities in allergy and clinical immunology Kathleen C. Barnes, PhD Baltimore, Md This activity is available for CME credit. See page 45A for important information. The striking racial and ethnic disparities in disease prevalence for common disorders, such as allergic asthma, cannot be Abbreviations used explained entirely by environmental, social, cultural, or CF: Cystic fibrosis economic factors, and genetic factors should not be ignored. CFTR: Cystic fibrosis transmembrane conductance Unfortunately, genetic studies in underserved minorities are regulator hampered by disagreements over the biologic construct of race CTLA4: Cytotoxic T lymphocyte–associated 4 and logistic issues, including admixture of different races and LD: Linkage disequilibrium ethnicities. Current observations suggest that the frequency NOS: Nitric oxide synthase of high-risk variants in candidate genes can differ between SNP: Single nucleotide polymorphism African Americans, Puerto Ricans, and Mexican Americans, and this might contribute to the differences in disease prevalence. Maintenance of certain allelic variants in the population over time might reflect selective pressures in influences (ie, gene-environment interactions). Con- previous generations.
    [Show full text]
  • The Views of Participants in DNA Biobanks
    The Views of Participants in DNA Biobanks Kelly E. Ormond,I Maureen E. Smith,II & Wendy A. WolfIII Abstract Biobanks are generally created with the long-term goal of establishing genotype-phenotype correlations. These resources collect and link DNA with health information for use in future genetic research studies. The biobanking process can vary with regard to specific characteristics in study design. Biobanks may extract DNA by using DNA from leftover samples or obtaining new DNA samples specifically for the biobank. Biobanks also vary in whether they use an opt- in or opt-out informed consent process. Some biobanks collect health information at a single point in time, while others “re-access” such information at designated points in the future to categorize subjects accurately into affected/unaffected status. These study design differences can influence the perception of participants and affect their willingness to participate. This paper will address the following three key issues: (1) why people decide to participate in DNA biobanks, (2) what enrollees understand about their participation in DNA biobanks, and (3) how participants feel about the possibility that biobanks will re-contact them, either to obtain new information for future studies or to share potential study results. Finally, we will suggest how information related to these three key issues ought to inform future study design for biobanks. I. INTRODUCTION.................................................................................................................81 II. WHY DO PEOPLE DECIDE TO PARTICIPATE IN DNA BIOBANKS?...........................82 III. WHAT DO ENROLLEES UNDERSTAND ABOUT THEIR PARTICIPATION IN A DNA BIOBANK? ..............................................................................................................................83 IV. HOW DO PARTICIPANTS FEEL ABOUT BIOBANK RE-CONTACT, AND HOW SHOULD THIS INFORMATION INFORM STUDY DESIGN?..............................................84 V.
    [Show full text]
  • Orthostatic Hypotension in a Cohort of Hypertensive Patients Referring to a Hypertension Clinic
    Journal of Human Hypertension (2015) 29, 599–603 © 2015 Macmillan Publishers Limited All rights reserved 0950-9240/15 www.nature.com/jhh ORIGINAL ARTICLE Orthostatic hypotension in a cohort of hypertensive patients referring to a hypertension clinic C Di Stefano, V Milazzo, S Totaro, G Sobrero, A Ravera, A Milan, S Maule and F Veglio The prevalence of orthostatic hypotension (OH) in hypertensive patients ranges from 3 to 26%. Drugs are a common cause of non-neurogenic OH. In the present study, we retrospectively evaluated the medical records of 9242 patients with essential hypertension referred to our Hypertension Unit. We analysed data on supine and standing blood pressure values, age, sex, severity of hypertension and therapeutic associations of drugs, commonly used in the treatment of hypertension. OH was present in 957 patients (10.4%). Drug combinations including α-blockers, centrally acting drugs, non-dihydropyridine calcium-channel blockers and diuretics were associated with OH. These pharmacological associations must be administered with caution, especially in hypertensive patients at high risk of OH (elderly or with severe and uncontrolled hypertension). Angiotensin-receptor blocker (ARB) seems to be not related with OH and may have a potential protective effect on the development of OH. Journal of Human Hypertension (2015) 29, 599–603; doi:10.1038/jhh.2014.130; published online 29 January 2015 INTRODUCTION stabilization, and then at 1 and 3 min after standing. The average of the Orthostatic hypotension (OH) is defined as the reduction in blood last two SBP and DBP values measured in the supine position and the pressure (BP) of at least 20 mmHg systolic and/or 10 mm Hg lowest value during standing were considered.
    [Show full text]
  • Hypertension and the Prothrombotic State
    Journal of Human Hypertension (2000) 14, 687–690 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh REVIEW ARTICLE Hypertension and the prothrombotic state GYH Lip Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK The basic underlying pathophysiological processes related to conventional risk factors, target organ dam- underlying the major complications of hypertension age, complications and long-term prognosis, as well as (that is, heart attacks and strokes) are thrombogenesis different antihypertensive treatments. Further work is and atherogenesis. Indeed, despite the blood vessels needed to examine the mechanisms leading to this being exposed to high pressures in hypertension, the phenomenon, the potential prognostic and treatment complications of hypertension are paradoxically throm- implications, and the possible value of measuring these botic in nature rather than haemorrhagic. The evidence parameters in routine clinical practice. suggests that hypertension appears to confer a Journal of Human Hypertension (2000) 14, 687–690 prothrombotic or hypercoagulable state, which can be Keywords: hypercoagulable; prothrombotic; coagulation; haemorheology; prognosis Introduction Indeed, patients with hypertension are well-recog- nised to demonstrate abnormalities of each of these Hypertension is well-recognised to be an important 1 components of Virchow’s triad, leading to a contributor to heart attacks and stroke. Further- prothrombotic or hypercoagulable state.4 Further- more, effective antihypertensive therapy reduces more, the processes of thrombogenesis and athero- strokes by 30–40%, and coronary artery disease by 2 genesis are intimately related, and many of the basic approximately 25%. Nevertheless the basic under- concepts thrombogenesis can be applied to athero- lying pathophysiological processes underlying both genesis.
    [Show full text]
  • Major Clinical Considerations for Secondary Hypertension And
    & Experim l e ca n i t in a l l C Journal of Clinical and Experimental C f a o r d l i a o Thevenard et al., J Clin Exp Cardiolog 2018, 9:11 n l o r g u y o Cardiology DOI: 10.4172/2155-9880.1000616 J ISSN: 2155-9880 Review Article Open Access Major Clinical Considerations for Secondary Hypertension and Treatment Challenges: Systematic Review Gabriela Thevenard1, Nathalia Bordin Dal-Prá1 and Idiberto José Zotarelli Filho2* 1Santa Casa de Misericordia Hospital, São Paulo, Brazil 2Department of scientific production, Street Ipiranga, São José do Rio Preto, São Paulo, Brazil *Corresponding author: Idiberto José Zotarelli Filho, Department of scientific production, Street Ipiranga, São José do Rio Preto, São Paulo, Brazil, Tel: +5517981666537; E-mail: [email protected] Received date: October 30, 2018; Accepted date: November 23, 2018; Published date: November 30, 2018 Copyright: ©2018 Thevenard G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Introduction: In this context, secondary arterial hypertension (SH) is defined as an increase in systemic arterial pressure (SAP) due to an identifiable cause. Only 5 to 10% of patients suffering from hypertension have a secondary form, while the vast majorities have essential hypertension. Objective: This study aimed to describe, through a systematic review, the main considerations on secondary hypertension, presenting its clinical data and main causes, as well as presenting the types of treatments according to the literary results.
    [Show full text]
  • Genetic Epidemiology Network of Arteriopathy (GENOA)
    Genetic Epidemiology Network of Arteriopathy (GENOA) Study Description The Genetic Epidemiology Network of Arteriopathy (GENOA) From its inception in 1995, GENOA's long-term objective was to elucidate the genetics of hypertension and its arteriosclerotic target-organ damage, including both atherosclerotic (macrovascular) and arteriolosclerotic (microvascular) complications involving the heart, brain, kidneys, and peripheral arteries. Two GENOA cohorts were originally ascertained (1995-2000) through sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of age. All siblings in the sibship were invited to participate, both normotensive and hypertensive. These include non-Hispanic White Americans from Rochester, MN (n =1583 at the 1st exam) and African Americans from Jackson, MS (N=1854 at the 1st exam). A third Hispanic American cohort from Starr County, TX, was ascertained through diabetic rather than hypertensive sibships (N=1812). The Hispanic American cohort is not included in this genetic analysis because no genome-wide genotype data is currently available for this cohort. Exclusion criteria for the white and African American cohorts were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. The GENOA data consists of biological samples (DNA, serum, urine) as well as demographic, anthropometric, environmental, clinical, biochemical, physiological, and genetic data for understanding the genetic predictors of diseases of the heart, brain, kidney, and peripheral arteries. Data were collected during two phases (Phase I from 1995-2000, Phase II from 2001-2004) and multiple ancillary studies (eg., chronic kidney disease assessments, brain MRIs, 24-hour urine and blood pressure assessments, etc). Written informed consent was obtained from all subjects and approval was granted by participating institutional review boards.
    [Show full text]
  • How to Document and Code for Hypertensive Diseases in ICD-10 THIS INSTALLMENT in FPM’S ICD-10 SERIES EXPLAINS the GUIDELINES for CODING HYPERTENSION
    How to Document and Code for Hypertensive Diseases in ICD-10 THIS INSTALLMENT IN FPM’S ICD-10 SERIES EXPLAINS THE GUIDELINES FOR CODING HYPERTENSION. Kenneth D. Beckman, MD, MBA, CPE, CPC ecause ICD-10 can be a distressing topic, let’s start or kidney disease. That code is I10, Essential (primary) with some good news: Hypertension has a limited hypertension. number of ICD-10 codes – only nine codes for pri- As in ICD-9, this code includes “high blood pressure” mary hypertension and five codes for secondary but does not include elevated blood pressure without a B hypertension. This makes the task of coding hypertension diagnosis of hypertension (that would be ICD-10 code relatively simple – well, at least compared to some of the R03.0). If a patient has progressed from elevated blood other ICD-10 complexities. pressure to a formal diagnosis of hypertension, a good Another positive change in ICD-10 is that the new documentation practice would be to include the reason for code set drops the previous reference to benign and progressing the formal diagnosis. Similarly, a single mildly malignant hypertension. As physicians, we are well aware elevated blood pressure reading should be coded with the that hypertension is never truly “benign,” and the removal R03.0 until the formal diagnosis is established. of this antiquated term is a welcome improvement in the Although various sources define hypertension slightly lexicon of diseases. differently, the provider should document elevated systolic But, of course, nothing is easy in ICD-10, and there are pressure above 140 or diastolic pressure above 90 with at several things you need to be aware of before we dig into least two readings on separate office visits.
    [Show full text]
  • Pharmacogenomics, How to Deal with Different Types of Variants in Next Generation Sequencing Data in the Personalized Medicine Area
    Journal of Clinical Medicine Review Pharmacogenomics, How to Deal with Different Types of Variants in Next Generation Sequencing Data in the Personalized Medicine Area Alireza Tafazoli 1,2 , Natalia Wawrusiewicz-Kurylonek 3, Renata Posmyk 3 and Wojciech Miltyk 1,* 1 Department of Analysis and Bioanalysis of Medicines, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, 15-089 Białystok, Poland; [email protected] 2 Clinical Research Centre, Medical University of Białystok, 15-276 Bialystok, Poland 3 Department of Clinical Genetics, Medical University of Białystok, 15-089 Białystok, Poland; [email protected] (N.W.-K.); [email protected] (R.P.) * Correspondence: [email protected]; Tel.: +48-857485845 Abstract: Pharmacogenomics (PGx) is the knowledge of diverse drug responses and effects in people, based on their genomic profiles. Such information is considered as one of the main directions to reach personalized medicine in future clinical practices. Since the start of applying next generation sequencing (NGS) methods in drug related clinical investigations, many common medicines found their genetic data for the related metabolizing/shipping proteins in the human body. Yet, the employing of technology is accompanied by big obtained data, which most of them have no clear guidelines for consideration in routine treatment decisions for patients. This review article talks about different types of NGS derived PGx variants in clinical studies and try to display the current and newly developed approaches to deal with pharmacogenetic data with/without clear guidelines for considering in clinical settings. Citation: Tafazoli, A.; Keywords: pharmacogenomics; NGS variants; personalized medicine Wawrusiewicz-Kurylonek, N.; Posmyk, R.; Miltyk, W.
    [Show full text]